ADAMA Reports First Quarter 2025 Results
PR Newswire
BEIJING and TEL AVIV, Israel, April 28, 2025
Positive net profit reported for Q1 2025
BEIJING and TEL AVIV, Israel, April 28, 2025 /PRNewswire/ -- ADAMA Ltd. (the "Company") (SZSE: 000553), today reported its financial results for the first quarter ended March 31(st) , 2025.
First Quarter 2025 Highlights:
-- Sales down 5% (-4% in RMB; -3% in CER) to $1,000 million, mainly
reflecting stable volume and 4% decrease in prices
-- Adjusted gross profit up 5% to $303 million, representing an improvement
of gross margin from 27.2% in Q1 2024 to 30.3% in Q1 2025, mainly
reflecting the benefits of lower costs
-- Adjusted EBITDA up 21% to $160 million representing an improvement of
EBITDA margin from 12.5% in Q1 2024 to 16.0% in Q1 2025
-- Adjusted net income of $44 million compared to a loss of $10 million in
Q1 2024; Reported net income up to $21 million from a loss of $32 million
in Q1 2024
-- Operating cash flow improved by $75 million; -$29 million in Q1 2025 vs.
-$103 million in Q1 2024
-- Free cash flow improved by $108 million, -$86 million in Q1 2025 vs.
-$194 million in Q1 2024
Gaël Hili, President and CEO of ADAMA, said, "I'm encouraged to see additional positive data, which can be attributed to the ongoing implementation of ADAMA's Fight Forward strategic transformation plan. In addition to improved operational and free cash flow and continued growth of adjusted gross profit and EBITDA and their margins, in Q1 2025 we saw a positive quarterly net profit. I congratulate ADAMA's team for their efforts to improve operational efficiencies. Despite challenging market conditions, I'm optimistic our recent achievements provide momentum towards further success as we focus on providing long-term value both to our investors and to farmers throughout the world."
Table 1. Financial Performance Summary
-------------------------------------------------------------------------------
As Reported Adjustments Adjusted
---------------- --------------------- --------------------------
Q1 Q1 Q1 Q1 Q1 Q1 %
USD (m) 2025 2024 % Change 2025 2024 2025 2024 Change
---------- ------ -------- -------- ---- ----- ------- -------- -------
Revenues 1,000 1,057 (5 %) - - 1,000 1,057 (5 %)
------ -------- -------- ---- ----- ------- -------- -------
Gross
profit 272 256 6 % 31 32 303 288 5 %
% of
sales 27.2 % 24.2 % 30.3 % 27.2 %
---------- ------ -------- -------- ---- ----- ------- -------- -------
Operating
income
$(EBIT)$ 70 51 38 % 26 21 96 72 34 %
% of
sales 7.0 % 4.8 % 9.6 % 6.8 %
---------- ------ -------- -------- ---- ----- ------- -------- -------
Income
(loss)
before
taxes 18 (21) 23 23 42 2 2189 %
% of
sales 1.8 % (2.0 %) 4.2 % 0.2 %
---------- ------ -------- -------- ---- ----- ------- -------- -------
Net Income
(loss) 21 (32) 23 22 44 (10)
% of
sales 2.1 % (3.0 %) 4.4 % (0.9 %)
---------- ------ -------- -------- ---- ----- ------- -------- -------
EPS
- USD 0.0090 (0.0138) 0. 0188 (0.0042)
- RMB 0.0649 (0.0977) 0.1350 (0.0297)
---------- ------ -------- -------- ---- ----- ------- -------- -------
EBITDA 144 120 19 % 16 12 160 132 21 %
% of
sales 14.4 % 11.4 % 16.0 % 12.5 %
---------- ------ -------- -------- ---- ----- ------- -------- -------
Notes:
-- "As Reported" denotes the Company's financial statements according to the
Accounting Standards for Business Enterprises and the implementation
guidance, interpretations and other relevant provisions issued or revised
subsequently by the Chinese Ministry of Finance (the "MoF) (collectively
referred to as "ASBE"). Note that in the reported financial statements,
according to the ASBE guidelines [IAS 37], certain items (specifically
certain transportation costs and certain idleness charges) are classified
under COGS. Please see the appendix to this release for further
information.
-- Relevant income statement items contained in this release are also
presented on an "Adjusted" basis, which exclude items that are of a
transitory or non-cash/non-operational nature that do not impact the
ongoing performance of the business, and reflect the way the Company's
management and the Board of Directors view the performance of the Company
internally. The Company believes that excluding the effects of these
items from its operating results allows management and investors to
effectively compare the true underlying financial performance of its
business from period to period and against its global peers. A detailed
summary of these adjustments appears in the appendix below.
-- The number of shares used to calculate both basic and diluted earnings
per share in both Q1 2025 and 2024 is 2,329.8 million shares.
-- In this table and all tables in this release numbers may not sum due to
rounding.
The General Crop Protection $(CP)$ Market Environment
Continuing the trend from 2024, key commodity crop prices remained subdued in Q1 2025, pressuring farmer income, despite some ease in the prices of inputs.
While channel inventory levels continue to ease following pandemic-era stockpiling, the high-interest rate environment coupled with ample product supply driven by significant over-capacity production of active ingredients in China, continue to contribute to low active ingredient ("AI") prices and a just-in-time purchasing approach by the channel.[1]
Portfolio Development Update
In Q1 2025, ADAMA continued to register and launch multiple new products in markets across the globe, adding on to its differentiated product portfolio. As part of the Fight Forward plan, the Company is focused on improving its overall portfolio mix, particularly by targeting the Value Innovation segment, with the intent of improving value delivered to all stakeholders.
In Q1 2025, launches of differentiated products included:
-- Cazado in Canada: A novel OD herbicide formulation combining Pinoxaden
and Thiencarbazone-methyl, offering wheat growers the first in-crop
solution to effectively control wild oats and proactively combat grassy
weed resistance.
-- Prothioconazole-based Products Expansion: ADAMA continued to extend its
Prothioconazole-based portfolio, launching several combination and solo
formulations across EU and other key markets. Products such as Forapro$(R)$,
Maganic, PYRADRA(R), AVASTEL(R), and Soratel(R) leverage ADAMA's
proprietary Asorbital(R) Formulation Technology for enhanced uptake and
systemic performance. Additionally, Maxentis(R)--a unique combination of
Prothioconazole and Azoxystrobin--was introduced to provide
broad-spectrum disease protection across multiple crops.
-- Gengfule in China: A powerful pre-emergent herbicide combining
S-metolachlor and Flumioxazin, utilizing TOV oil dispersion formulation
technology to offer broad-spectrum weed control with significant residual
effect.
-- Stemper in the United Kingdom and Denmark: A Trinexapac-ethyl formulation
that enhances crop resilience and lodging resistance, supporting improved
harvest outcomes for cereal growers.
-- Timeline FX in Romania and Poland, a post-emergence triple-active
herbicide combining Pinoxaden, Florasulam, and Fluroxypyr. This
combination offers broad-spectrum control of both broadleaf and grassy
weeds in cereal crops, providing farmers with an effective tool to manage
weed resistance and enhance crop yields.
Registrations of differentiated products during Q1 2025 included:
-- Temper More: Registered in the US. This new highly effective EW herbicide
formulation was developed using ADAMA's proprietary SESGAMA platform. It
combines Glufosinate-ammonium and S-metolachlor for a dual mode of action,
providing broad-spectrum burndown weed control and robust residual
control of grass and small-seeded broadleaf weeds.
-- Metamitron: Newly registered active ingredient in the US with both fruit
thinning and herbicide activities, depending of the formulation.
-- Brevis: Registered in the US, this highly effective fruit thinner based
on Metamitron offers a powerful solution for managing flowering and
fruiting on pome fruits.
-- Klinner: Registered in Brazil, this three-way mixture of Picoxystrobin,
Prothioconazole and Mancozeb is formulated using a unique technology that
enables broad-spectrum control of foliar diseases in soybeans.
-- Lince: Registered in Brazil. A WG formulation combining Atrazine and
Mesotrione, delivering effective control of a broad spectrum of weeds in
corn and sugarcane.
In addition, notable patents granted during Q1 2025 included:
-- New Zealand: A patent was granted for SESGAMA's proprietary formulation
technology.
-- China: A patent was granted for the proprietary formulation of Sierra(R)
-- Australia: A patent was granted for the proprietary formulation of
Zulu(R) XT
Geopolitical Situation
ADAMA is headquartered and has three manufacturing sites in Israel. The regional tensions which escalated on October 7, 2023, have had no material impact to-date on the Company's ability to support its markets or its consolidated financial results.
Regarding US tariff policies, the Company continues to closely monitor the situation and the potential impact on its global network.
'Fight Forward' Transformation Plan
In early 2024, ADAMA launched 'Fight Forward', a strategic transformation plan aimed at gradually delivering improved profit and cash targets over a three-year period. This plan has three main pillars: Optimize financial management, streamline ADAMA's operating model and focus on the Value Innovation segment. As part of the Fight Forward transformation plan, the Company has initiated organizational changes to improve efficiencies.
ESG update
ADAMA has published the Environmental, Social, and Corporate Governance $(ESG)$ report for the year ended 31 December 2024 (Link).
Financial Highlights
Revenues in the first quarter declined by approximately 5% (-4% in RMB; -3% in CER) to $1,000 million, reflecting stable volumes, a decrease of 4% in prices and negative foreign exchange impacts. The Company maintained stable volumes, with declines in Turkey (for which Q1 is generally the most significant quarter of a year) and the continued shifting away from selected low profit products, amid improvement of channel inventories in most regions. The lower prices were due to just-in-time purchasing patterns of the channel and the pressure of low AI prices in light of overcapacity and a higher interest rate environment.
Table 2. Regional Sales Performance
Q1 2025 Q1 2024 Change Change
$m $m USD CER
----------------------------- ------- ------- ------ ------
Europe, Africa & Middle East 356 377 (6 %) (4 %)
------------------------------ ------- ------- ------ ------
North America 219 191 15 % 15 %
------------------------------ ------- ------- ------ ------
Latin America 147 191 (23 %) (15 %)
------------------------------ ------- ------- ------ ------
Asia Pacific 278 298 (7 %) (5 %)
------------------------------ ------- ------- ------ ------
Of which China 166 154 8 % 8 %
------------------------------ ------- ------- ------ ------
Total 1,000 1,057 (5 %) (3 %)
------------------------------ ------- ------- ------ ------
Notes:
-- CER: Constant Exchange Rates
-- As part of ADAMA's business optimization program, on January 1, 2025, ADAMA's South Africa business was reclassified from APAC operations to EAME operations. To enable meaningful comparisons, the 2024 data presented here includes South Africa under EAME.
-- Numbers may not sum due to rounding
Europe, Africa & Middle East (EAME): Revenues in Q1 2025 were down compared to Q1 2024, with slight decrease in pricing and stable volume. Volume improvements in Europe were more than offset by declines in Turkey. Channel levels have returned to normal, but competition remains strong.
North America: Consumer & Professional Solutions: Q1 sales grew significantly compared to Q1 2024, and margins remained strong. ADAMA's US Ag market grew, with slight improvements in volumes and pricing. Pricing in Canada continues to experience increased competition and downward price pressure, though sales are currently up on significantly stronger volume, partially due to normalized channel stocking behavior.
Latin America: In Brazil, Q1 revenues declined YoY due to lower prices, lower volumes and weak currency. Similarly, in the rest of LATAM, sales were weaker in Q1 as compared to Q1 2024, mostly due to increased competition and just-in-time purchasing patterns.
Asia-Pacific (APAC): Sales continued to experience pricing pressure, with sales declining compared to Q1 2024. The declines reflected both the ample over supply of Chinese generics and the Company's decision to optimize regional layouts.
In China, first quarter sales were up. AI sales increased, driven by significant business growth which more than offset weak prices, amid gradual recovery of global demand. Non-ag sales also increased supported mainly by higher prices of caustic soda. Declines in the branded formulations business mainly reflected the impacts of market competition on prices and volumes.
Reported gross profit in the first quarter increased 6% to $272 million (gross margin of 27.2%) from $256 million (gross margin of 24.2%) in the same quarter last year.
Adjustments to reported results: The adjusted gross profit includes reclassification of inventory impairment, taxes and surcharge and excludes certain transportation costs (classified under operating expenses).
Adjusted gross profit in the first quarter increased 5% to $303 million (gross margin of 30.3%) from $288 million (gross margin of 27.2%) in the same quarter last year.
The higher gross profit and margin in the first quarter mainly reflected the positive impact of lower costs of new inventory sold, more than compensating for lower prices and negative exchange rate impacts.
Operating expenses reported in the first quarter were $202 million (20.2% of sales), compared to $206 million (19.4% of sales) in the corresponding period last year.
Adjustments to reported results: Please refer to the explanation regarding adjustments to the gross profit in respect to certain transportation costs, taxes and surcharges and inventory impairment. Non-operating income and expenses are also reclassified into adjusted operating expenses.
The Company recorded certain non-operational items within its reported operating expenses amounting to $25 million in Q1 2025 in comparison to $19 million in Q1 2024. These include mainly: i. non-cash amortization charges in respect of transfer assets received from Syngenta related to the 2017 ChemChina-Syngenta acquisition; ii. non-cash amortization net charges related to intangible assets created as part of the Purchase Price Allocation $(PPA)$ on acquisitions, with no impact on the ongoing performance of the companies acquired; and iii. restructuring and advisory costs incurred as part of the implementation of the Fight Forward transformation plan. For further details on these non-operational items, please see the appendix to this release.
Adjusted operating expenses in the first quarter were $207 million (20.7% of sales), compared to $216 million (20.5% of sales) in the corresponding period last year.
The lower operating expenses mainly reflected benefits from continued tight OPEX management measures as part of the Company's transformation plan, and the positive impact of foreign exchange rates.
Operating income reported in the first quarter increased 38% to $70 million (7.0% of sales) compared to $51 million (4.8% of sales) in the same quarter last year.
Adjusted operating income in the first quarter increased 34% to $96 million (9.6% of sales) from $72 million (6.8% of sales) in the same quarter last year. The increase in operating income was a combined result of higher gross profit and lower operating expenses.
EBITDA reported in the first quarter increased 19% to $144 million (14.4% of sales) from $120 million (11.4% of sales) in the same quarter last year.
Adjusted EBITDA in the first quarter increased 21% to $160 million (16.0% of sales) from $132 million (12.5% of sales) in the same quarter last year.
Adjusted financial expenses amounted to $54 million in the first quarter, compared to $70 million in the corresponding period last year.
In the first quarter of 2025, financial expenses were lower mainly due to lower hedging costs and lower interest paid on debt following improved efficiency of cash management in light of the positive cash flow achieved in the previous twelve months.
Adjusted taxes on income in the first quarter amounted to an income of $2 million, compared to expenses of $12 million in the corresponding period last year. The tax income in the first quarter of 2025 was mainly due to the non-cash impact of the stronger BRL and the method of calculation of tax assets related to unrealized profits.
Net income reported in the first quarter increased to $21 million, compared to a net loss of $32 million in the corresponding period last year.
After reflecting the impact of the aforementioned extraordinary and non-operational charges, adjusted net income in the first quarter increased to $44 million, compared to a loss of $10 million in the corresponding period last year.
Trade working capital as of March 31, 2025, was $2,256 million compared to $2,583 million as of March 31, 2024. The decrease in working capital was mainly because of the decline in the level of inventory, including that of finished goods, from $1,807 million as of March 31, 2024 to $1,604 million as of March 31, 2025. The decline of inventories resulted from continued implementation of selective procurement and enhanced inventory management. As the Company improved its payable terms following implementation of initiatives as part of the Company's transformation plan, trade payables slightly increased while procurement was strictly managed. The decrease in receivables reflected the intensive collections and the lower sales.
Cash Flow: Operating cash flow of $29 million was consumed in the first quarter of 2025, compared to $103 million in the same quarter last year. The negative operating cash flow, which is seasonally typical for ADAMA in the first quarter, was significantly improved due to intensive collection and improved business earnings.
Net cash used in investing activities was $37 million in the first quarter of 2025, compared to $67 million in the same quarter last year. The lower cash used in investing activities in Q1 2025 reflected prioritization of investments in ADAMA's manufacturing facilities and portfolio optimization.
Free cash flow of $86 million was consumed in the first quarter of 2025, compared to $194 million in the same quarter last year, reflecting the aforementioned operating and investing cash flow dynamics.
Table 3. Revenues by operating segment
Sales by segment
Q1 2025 Q1 2024
USD (m) % USD (m) %
------------------------------ -------- ----- -------- -----
Crop Protection 906 91 % 961 91 %
Intermediates and Ingredients 94 9 % 96 9 %
------------------------------ -------- ----- -------- -----
Total 1,000 100 % 1,057 100 %
------------------------------ -------- ----- -------- -----
Sales by product category
Q1 2025 Q1 2024
USD (m) % USD (m) %
------------------------------ -------- ----- -------- -----
Herbicides 445 45 % 454 43 %
Insecticides 243 24 % 290 27 %
Fungicides 217 22 % 217 21 %
Intermediates and Ingredients 94 9 % 96 9 %
------------------------------ -------- ----- -------- -----
Total 1,000 100 % 1,057 100 %
------------------------------ -------- ----- -------- -----
Notes:
The sales split by product category is provided for convenience purposes only and is not representative of the way the Company is managed or in which it makes its operational decisions.
Numbers may not sum due to rounding.
Further Information
All filings of the Company, together with a presentation of the key financial highlights of the period, can be accessed through the Company website at www.adama.com.
About ADAMA
ADAMA Ltd. is a global leader in crop protection, providing practical solutions to farmers across the world to combat weeds, insects and disease. Our culture empowers ADAMA's people to actively listen to farmers and ideate from the field. ADAMA's diverse portfolio of existing active ingredients, coupled with its leading formulation capabilities and proprietary formulation technology platforms, uniquely position the company to develop high-quality, innovative and sustainable products, to address the many challenges farmers and customers face today. ADAMA serves customers in dozens of countries globally, with direct presence in all top 20 markets. For more information, visit us at www.ADAMA.com and follow us on X at @ADAMAAgri.
Contact
Joshua Phillipson Zhujun Wang
Global Investor Relations China Investor Relations
Email: ir@adama.com Email: irchina@adama.com
Abridged Adjusted Consolidated Financial Statements
The following abridged consolidated financial statements and notes have been prepared as described in Note 1 in this appendix. While prepared based on the principles of Chinese Accounting Standards $(ASBE.UK)$, they do not contain all of the information which either ASBE or IFRS would require for a complete set of financial statements, and should be read in conjunction with the consolidated financial statements of both ADAMA Ltd. and Adama Agricultural Solutions Ltd. as filed with the Shenzhen and Tel Aviv Stock Exchanges, respectively.
Relevant income statement items contained in this release are also presented on an "Adjusted" basis, which exclude items that are of a one-time or non-cash/non-operational nature that do not impact the ongoing performance of the business, and reflect the way the Company's management and the Board of Directors view the performance of the Company internally. The Company believes that excluding the effects of these items from its operating results allows management and investors to effectively compare the true underlying financial performance of its business from period to period and against its global peers.
Abridged Consolidated Income Statement for the First Quarter
------------------------------------------------------------------------------
Q1 2025 Q1 2024 Q1 2025 Q1 2024
Adjusted([2]) USD (m) USD (m) RMB (m) RMB (m)
-------------------------------------- -------- -------- -------- --------
Revenues 1,000 1,057 7,173 7,509
Cost of Sales 694 767 4,981 5,450
Other costs 3 2 20 13
-------------------------------------- -------- -------- -------- --------
Gross profit 303 288 2,172 2,046
% of revenue 30.3 % 27.2 % 30.3 % 27.2 %
Selling & Distribution expenses 155 169 1,116 1,198
General & Administrative expenses 37 36 267 254
Research & Development expenses 14 16 103 112
Other operating expenses 0 (4) 2 (26)
Total operating expenses 207 216 1,487 1,538
% of revenue 20.7 % 20.5 % 20.7 % 20.5 %
-------------------------------------- -------- -------- -------- --------
Operating income (EBIT) 96 72 686 508
% of revenue 9.6 % 6.8 % 9.6 % 6.8 %
Financial expenses 54 70 387 495
-------------------------------------- -------- -------- -------- --------
Income before taxes 42 2 298 13
Taxes on Income (2) 12 (16) 82
-------------------------------------- -------- -------- -------- --------
Net income (loss) 44 (10) 315 (69)
% of revenue 4.4 % (0.9 %) 4.4 % (0.9 %)
Adjustments 23 22 164 158
-------------------------------------- -------- -------- -------- --------
Reported net income (loss) 21 (32) 151 (228)
% of revenue 2.1 % (3.0 %) 2.1 % (3.0 %)
Adjusted EBITDA 160 132 1,149 938
% of revenue 16.0 % 12.5 % 16.0 % 12.5 %
-------------------------------------- -------- -------- -------- --------
Adjusted EPS[3] -- Basic 0.0188 (0.0042) 0.1350 (0.0297)
-- Diluted 0.0188 (0.0042) 0.1350 (0.0297)
-------------------------------------- -------- -------- -------- --------
Reported EPS(5) -- Basic 0.0090 (0.0138) 0.0649 (0.0977)
--
Diluted 0.0090 (0.0138) 0.0649 (0.0977)
-------------------------------------- -------- -------- -------- --------
Abridged Consolidated Balance Sheet
March 31 March 31 March 31 March 31
2025 2024 2025 2024
USD (m) USD (m) RMB (m) RMB (m)
-------------------------------------- -------- -------- -------- --------
Assets
Current assets:
Cash at bank and on hand 518 523 3,720 3,710
Bills and accounts receivable 1,400 1,521 10,049 10,789
Inventories 1,604 1,807 11,510 12,824
Other current assets, receivables
and prepaid expenses 238 230 1,708 1,663
-------------------------------------- -------- -------- -------- --------
Total current assets 3,760 4,081 26,988 28,955
-------------------------------------- -------- -------- -------- --------
Non-current assets:
Fixed assets, net 1,623 1,767 11,649 12,533
Rights of use assets 77 86 551 607
Intangible assets, net 1,360 1,447 9,760 10,267
Deferred tax assets 197 223 1,413 1,585
Other non-current assets 94 106 673 755
Total non-current assets 3,350 3,629 24,046 25,747
-------------------------------------- -------- -------- -------- --------
Total assets 7,110 7,710 51,034 54,703
-------------------------------------- -------- -------- -------- --------
Liabilities
Current liabilities:
Loans and credit from banks and
other lenders 1,056 1,039 7,583 7,369
Bills and accounts payable 771 754 5,537 5,350
Other current liabilities 834 749 5,983 5,312
Total current liabilities 2,661 2,541 19,103 18,031
-------------------------------------- -------- -------- -------- --------
Long-term liabilities:
Loans and credit from banks and
other lenders 285 476 2,044 3,374
Debentures 865 965 6,207 6,848
Deferred tax liabilities 37 41 266 294
Employee benefits 77 97 554 687
Other long-term liabilities 519 536 3,725 3,806
-------- -------- -------- --------
Total long-term liabilities 1,783 2,115 12,796 15,009
-------------------------------------- -------- -------- -------- --------
Total liabilities 4,444 4,657 31,899 33,040
-------------------------------------- -------- -------- -------- --------
Equity
Total equity 2,666 3,053 19,135 21,663
-------------------------------------- -------- -------- -------- --------
Total liabilities and equity 7,110 7,710 51,034 54,703
-------------------------------------- -------- -------- -------- --------
Abridged Consolidated Cash Flow Statement for the First Quarter
Q1 2025 USD Q1 2024 USD Q1 2025 RMB Q1 2024 RMB
(m) (m) (m) (m)
---------------- ------------- ------------- -------------- --------------
Cash flow from
operating
activities:
Cash flow
from
operating
activities (29) (103) (207) (735)
Cash flow from
operating
activities (29) (103) (207) (735)
---------------- ------------- ------------- -------------- --------------
Investing
activities:
Acquisitions
of fixed and
intangible
assets (44) (66) (317) (468)
Net cash
received
from
disposal of
fixed
assets,
intangible
assets and
others 2 1 14 4
Other
investing
activities 6 (1) 41 (8)
Cash flow used
for investing
activities (37) (67) (262) (473)
---------------- ------------- ------------- -------------- --------------
Financing
activities:
Receipt of
loans from
banks and
other
lenders 137 172 980 1,218
Repayment of
loans from
banks and
other
lenders (66) (195) (472) (1,383)
Interest
payment and
other (20) (24) (146) (168)
Other
financing
activities 23 49 162 349
Cash flow from
financing
activities 73 2 523 17
---------------- ------------- ------------- -------------- --------------
Effects of
exchange rate
movement on
cash and cash
equivalents 1 0 (1) 13
---------------- ------------- ------------- -------------- --------------
Net change in
cash and cash
equivalents 8 (167) 53 (1,178)
---------------- ------------- ------------- -------------- --------------
Cash and cash
equivalents at
the beginning
of the period 499 686 3,584 4,857
Cash and cash
equivalents at
the end of the
period 507 519 3,637 3,679
---------------- ------------- ------------- -------------- --------------
Free Cash Flow 86 (194) (615) (1,376)
---------------- ------------- ------------- -------------- --------------
Notes to Abridged Consolidated Financial Statements
Note 1: Basis of preparation
Basis of presentation and accounting policies: The abridged consolidated financial statements for the quarters ended March 31, 2025 and 2024 incorporate the financial statements of ADAMA Ltd. and of all of its subsidiaries (the "Company"), including Adama Agricultural Solutions Ltd. ("Solutions") and its subsidiaries.
The Company has adopted the Accounting Standards for Business Enterprises (ASBE) issued by the Ministry of Finance (the "MoF") and the implementation guidance, interpretations and other relevant provisions issued or revised subsequently by the MoF (collectively referred to as "ASBE").
The abridged consolidated financial statements contained in this release are presented in both Chinese Renminbi (RMB), as the Company's shares are traded on the Shenzhen Stock Exchange, as well as in United States dollars ($) as this is the major currency in which the Company's business is conducted. For the purposes of this release, a customary convenience translation has been used for the translation from RMB to US dollars, with Income Statement and Cash Flow items being translated using the quarterly average exchange rate, and Balance Sheet items being translated using the exchange rate at the end of the period.
The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated.
Note 2: Abridged Financial Statements
For ease of use, the financial statements shown in this release have been abridged as follows:
Abridged Consolidated Income Statement:
-- "Gross profit" in this release is revenue less costs of goods sold, taxes
and surcharges, inventory impairment and other idleness charges (in
addition to those already included in costs of goods sold); part of the
idleness charges is removed in the Adjusted financial statements
-- "Other operating expenses" includes impairment losses (not including
inventory impairment); gain (loss) from disposal of assets and
non-operating income and expenses
-- "Operating expenses" in this release differ from those in the formally
reported financial statements in that certain transportation costs have
been reclassified from COGS to Operating Expenses.
-- "Financial expenses" includes net financing expenses and gains/losses
from changes in fair value.
Abridged Consolidated Balance Sheet:
-- "Other current assets, receivables and prepaid expenses" includes
financial assets held for trading; financial assets in respect of
derivatives; prepayments; other receivables; and other current assets
-- "Fixed assets, net" includes fixed assets and construction in progress
-- "Intangible assets, net" includes intangible assets and goodwill
-- "Other non-current assets" includes other equity investments; long-term
equity investments; long-term receivables; investment property; and other
non-current assets
-- "Loans and credit from banks and other lenders" includes short-term loans
and non-current liabilities due within one year
-- "Other current liabilities" includes financial liabilities in respect of
derivatives; payables for employee benefits, taxes, interest, dividends
and others; advances from customers and other current liabilities
-- "Other long-term liabilities" includes long-term payables, provisions,
deferred income and other non-current liabilities
Income Statement Adjustments
------------------------------------------------------------------------------
Q1 2025 Q1 2024 Q1 2025 Q1 2024
USD (m) USD (m) RMB (m) RMB (m)
-------------------------------------- -------- -------- -------- --------
Reported Net Income (Loss) 21 (32) 151 (228)
-------------------------------------- -------- -------- -------- --------
Adjustments to COGS & Operating
Expenses:
--------------------------------------
1. Amortization of acquisition-related
PPA and other acquisition related
costs 4 4 26 26
2. Amortization of Transfer assets
received and written-up due to 2017
ChemChina-Syngenta transaction
(non-cash) 5 5 39 36
3. ASBEs classifications COGS impact (30) (30) (215) (214)
4. ASBEs classifications OPEX impact 30 30 215 214
5. Restructuring and advisory costs 16 11 115 80
6. Other 1 1 5 6
Total Adjustments to Operating Income
(EBIT) 26 21 185 148
Total Adjustments to EBITDA 16 12 118 82
Adjustments to Financing Expenses:
--------------------------------------
7. Non-cash adjustment related to put
options revaluation 3 1 24 5
8. Arbitration decision related to a
controlled subsidiary (4) - (32) -
9. Other financing expenses (1) 1 (10) 11
Adjustments to Taxes:
--------------------------------------
Taxes impact - (1) (3) (6)
Total adjustments to Net Income (Loss) 23 22 164 158
-------------------------------------- -------- -------- -------- --------
Adjusted Net Income (Loss) 44 (10) 315 (69)
-------------------------------------- -------- -------- -------- --------
Notes:
1. Amortization of acquisition-related PPA and other acquisition related
costs: Related mainly to the non-cash amortization of intangible assets
created as part of the Purchase Price Allocation (PPA) on acquisitions,
with no impact on the ongoing performance of the companies acquired, as
well as other M&A-related costs.
2. Amortization of Transfer assets received and written-up due to 2017
ChemChina-Syngenta transaction (non-cash): The proceeds from the
Divestment of crop protection products in connection with the approval by
the EU Commission of the acquisition of Syngenta by ChemChina, net of
taxes and transaction expenses, were paid to Syngenta in return for the
transfer of a portfolio of products in Europe of similar nature and
economic value. Since the products acquired from Syngenta are of the same
nature and with the same net economic value as those divested, and since
in 2018 the Company adjusted for the one-time gain that it made on the
divested products, the additional amortization charge incurred due to the
written-up value of the acquired assets is also adjusted to present a
consistent view of Divestment and Transfer transactions, which had no net
impact on the underlying economic performance of the Company. These
additional amortization charges will continue until 2032 but at a
reducing rate, yet will still be at a meaningful level until 2028.
3. & 4. ASBEs classifications COGS impact: according to the ASBE guidelines
[IAS 37], certain items (specifically certain transportation costs) are
classified under COGS.
4. Restructuring and advisory costs: The Company initiated its Fight Forward
transformation plan in early 2024. Part of the plan includes
restructuring its organizational structure, workforce and managerial
processes, and as a result thereof, the Company recorded restructuring
and advisory costs.
5. Other: Mainly attributable to accelerated depreciation associated with
facilities upgrade.
6. Non-cash adjustment related to put options revaluation: expenses due to
revaluation of put options attributed to minority stake in subsidiaries
7. Arbitration decision related to a controlled subsidiary: An arbitration
case related to a controlled subsidiary incurred a one-time income.
Exchange Rate Data for the Company's Principal Functional Currencies
----------------------------------------------------------------------------
March 31 Q1 Average
--------- ------------------------------- ------------------------------
2025 2024 Change 2025 2024 Change
--------- --------- --------- --------- --------- -------- ---------
EUR/USD 1.082 1.081 0.1 % 1.051 1.086 -3.2 %
USD/BRL 5.742 4.996 -14.9 % 5.845 4.953 -18.0 %
USD/PLN 3.864 3.989 3.1 % 3.996 3.992 -0.1 %
USD/ZAR 18.21 18.87 3.5 % 18.492 18.896 2.1 %
AUD/USD 0.625 0.651 -4.0 % 0.627 0.658 -4.6 %
GBP/USD 1.294 1.264 2.4 % 1.259 1.268 -0.8 %
USD/ILS 3.718 3.681 -1.0 % 3.613 3.660 1.3 %
USD L 3M 4.30 % 5.30 % 4.30 % 5.32 %
--------- --------- --------- --------- --------- -------- ---------
March 31 Q1 Average
--------- ----------------------- -------------------------
2025 2024 Change 2025 2024 Change
--------- ----- ------- ------- ------- ------- -------
USD/RMB 7.765 7.095 9.4 % 7.763 7.103 9.3 %
EUR/RMB 7.178 7.670 -6.4 % 7.176 7.678 -6.5 %
RMB/BRL 0.800 0.704 -13.6 % 0.815 0.697 -16.8 %
RMB/PLN 0.538 0.704 23.6 % 0.557 0.562 0.9 %
RMB/ZAR 2.538 2.659 4.6 % 2.577 2.660 3.1 %
AUD/RMB 4.487 4.619 -2.9 % 4.502 4.672 -3.6 %
GBP/RMB 9.016 0.562 -0.1 % 9.288 8.969 3.6 %
RMB/ILS 0.518 0.519 0.2 % 0.503 0.515 2.3 %
RMB L 3M 1.912 2.157 % -11.4 % 1.811 % 2.284 % -20.7 %
--------- ----- ------- ------- ------- ------- -------
Forward looking statement:
This press release published by ADAMA Ltd. or ADAMA Agricultural Solutions Ltd. (together the "Company") is for marketing and information purposes only, and contains forward-looking statements which are based on Company's management's beliefs and assumptions and on information currently available to the Company's management. By this press release, the Company does not intend to give, and the press release does not constitute, professional or business advice or an offer or recommendation to perform any transaction in the Company's securities. The accuracy, completeness and/or adequacy of the content of this press release, as well as any estimation and/or assessment included in this press release, if at all, is not warranted or guaranteed and the Company disclaims any intention and/or obligation to comply with such content. The Company shall not be liable for any loss, claim, liability or damage of any kind resulting from your reliance on, or reference to, any detail, fact or opinion presented herein. The Company's assessments are based on the information available to the Company as of the date hereof, and may not be realized or be realized in a different manner than the Company estimates, inter alia, due to factors out of the Company's control, including the risk factors listed in the Company's annual reports and changes in the industry or potential operations of the Company's competitors. Any content contained herein shall not constitute or be construed as any regulatory, valuation, legal, tax, accounting and investment advice or any advice of any kind or any part of it, nor shall they constitute or be construed as any recommendation, solicitation, offer or commitment (or any part of it) to buy, sell, subscribe for or underwrite any securities, provide any credit or insurance or engage in any transactions. Before entering into any transactions, you shall ensure that you fully understand the potential risks and returns of such transactions. Before making such decisions, you shall consult the advisors you think necessary, including your accountant, investment advisor and legal and tax specialists. The Company and its affiliates, controlling persons, directors, officials, partners, employees, agents, representatives or their advisors shall not assume any responsibilities of any kind (including negligence or others) for the use of and reliance on such information by you or any person to whom such information are provided.
[1] Sources: AgbioInvestor Market Insight (February 2025), peer quarterly financial results, internal sources
[2] For an analysis of the differences between the adjusted income statement items and the income statement items as reported in the financial statements, see below "Analysis of Gaps between Adjusted Income Statement and Income Statement in Financial Statements".
[3] The number of shares used to calculate both basic and diluted earnings per share in both Q1 2025 and 2024 is 2,329.8 million shares.
Logo - https://mma.prnewswire.com/media/799829/Adama_Agricultural_Solutions_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/adama-reports-first-quarter-2025-results-302439690.html
SOURCE ADAMA Ltd.
(END) Dow Jones Newswires
April 28, 2025 08:41 ET (12:41 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。